Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG’s Treg-focused action as a potential breakthrough for Alopecia areata treatment.
Latest Ratings for NKTR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Oppenheimer | Upgrades | Perform | Outperform |
| Nov 2021 | Benchmark | Upgrades | Hold | Buy |
| Nov 2021 | SVB Leerink | Maintains | Market Perform |
